The Kaplan-Meier plotter database analysis showed that the median survival time of patients with EZH2 mRNA high expression is 54.17 months, and the median survival time of patients with EZH2 mRNA low expression is 79.50 months (HR = 1.31 and p < 0.05), suggesting EZH2 high expression in NSCLC tissues indicates a poor prognosis and has significant correlation with cancer stage and pathological type. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.